---

Andy Skibo

Head of Global Biologics Operations & Global Engineering, AstraZeneca/Medimmune

“I am passionate about ensuring that we (both AstraZeneca/MedImmune specifically, and our biopharmaceutical industry as a whole) have a long-range biologics supply capability,” says Andy. He would like to see the pharma industry work closer with regulatory agencies to find ways to dramatically reduce the cost of developing new drugs – specifically the cost of clinical trials – without sacrificing product safety or affecting patient risks.

---

Part of the Power List 2018

The World’s Top 100 Medicine Makers

Bringing new drugs to patients is an incredibly difficult task that involves numerous indispensable actors – from pioneering entrepreneurs and CEOs, to industry experts, to dedicated researchers, to regulators who keep everyone on the right tracks.

Go to The Power List 2018